Skip to main content

Table 3 Description of corticosteroid use among critically ill patients with H1N1pdm09

From: The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness

Medication variable Median (q1, q3) or n (%)a
Corticosteroid treatment, n (%) 280 (46.1)
Corticosteroid prescribed, n (%)  
 Prednisone 189 (34.4)
 Methylprednisolone 177 (32.2)
 Hydrocortisone 161 (29.3)
 Dexamethasone 22 (4.0)
 Cortisone 1 (0.2)
Duration of corticosteroids, days 7.0 (4.0, 13.0)
Dose, hydrocortisone equivalents per dayb (mg) 227 (154, 443)
Dose, hydrocortisone equivalents per day (mg/kg) 3.1 (1.7, 5.8)
Duration between onset of critical illness and corticosteroid initiation, days 0.0 (0.0, 3.0)
Duration between hospital admission and corticosteroid initiation, days 2.0 (1.0, 8.0)
Duration between onset of ventilation and corticosteroid initiation, days 1.0 (0.0, 3.0)
PaO2/FiO2 before corticosteroid administrationc (cmH2O) 140 (91, 220)
Positive End-Expiratory Pressure before corticosteroid administrationc (cmH2O) 10.0 (8.0, 14.0)
SOFA cardiovascular score before corticosteroid administration 2.0 (0.0, 3.0)
  1. SOFA Sequential Organ Failure Assessment (SOFA score of 2 indicates patient receiving dopamine ≤5 μg/kg/minute or dobutamine any dose) [33], FiO 2 fraction of inspired oxygen, PaO 2 partial pressure of oxygen in arterial blood
  2. aDenominators may vary for each category
  3. b http://www.medcalc.com/steroid.html
  4. cPaO2/FiO2 ratio and positive end-expiratory pressure were recorded only on days 1, 3, 7, 14, and 28